News & Updates

In part 1 (dose ranging with and without dose escalation) of the phase II MariTide study, significant weight reduction and robust glycaemic improvement were achieved with maridebart cafraglutide (MariTide) – the first, long-acting, GIPR* antagonist and GLP-1R** agonist – in individuals with obesity or overweight and type 2 diabetes (T2D).

Subcutaneous tocilizumab, used either as a monotherapy or in combination with methotrexate (MTX), shows greater efficacy than MTX alone in Chinese patients with active rheumatoid arthritis (RA) who have not adequately responded to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs).

Apremilast, an oral immunomodulating phosphodiesterase-4 inhibitor, reduces inflammation in individual joints and clinical dactylitis as per MRI in patients with psoriatic arthritis (PsA), according to the results of a dynamic contrast-enhanced MRI (DCE-MRI) analysis of the phase IV, open-label MOSAIC study.